China Approves Walvax's Third mRNA COVID-19 Vaccine Targeting Omicron JN.1 Strain
China's National Medical Products Administration (NMPA) has granted approval for a COVID-19 mRNA vaccine developed by Yuxi Watson Biotechnology Co., Ltd., a subsidiary of Walvax Biotechnology Co., Ltd. This vaccine is intended for adults aged 18 and above and specifically targets the Omicron JN.1 strain of SARS-CoV-2. This marks the third mRNA COVID-19 vaccine iteration from Walvax's proprietary platform. The vaccine is administered as a 0.15 mL injection containing 30 µg of mRNA encoding the Omicron JN.1 spike (S) protein, delivered via a lipid nanoparticle (LNP) system. The molecular design, manufacturing process, and formulation remain consistent with previous versions, with the only change being the antigen-encoding mRNA sequence. The LNP-formulated mRNA instructs host cells to produce the JN.1 S protein antigen, stimulating neutralizing antibody and T cell responses without introducing a live virus. This approval introduces a domestically developed mRNA option into China's vaccine landscape, which has...